retatrutide triple agonist glp-1 gip glucagon receptor UK Research Library ADA 2026: Retatrutide Revolution

PitchBook says Mochi is backed by the VC firm AngelList and other undisclosed investors

2 Although the pancreatic effects of GLP-1 (glucose-dependent insulin secretion and glucagon suppression) are well-established, its extrapancreatic actions are increasingly being recognised as critical to the therapeutic effects of GLP-1RAs

Clase CM, Carrero J-J, Ellison DH, Grams ME, Hemmelgarn BR, Jardine MJ, et al

It is about giving the body better inputs so it can produce better outputs

It was developed by Eli Lilly and entered the published Phase 2 program in 2023 with three parallel disease contexts: obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease

Hydration should start the moment you take your dose